| Similar Articles |
|---|
 |
The Motley Fool
June 15, 2005
Bobby Shethia |
A New Test for Quest The medical testing leader hopes to improve its steady performance via the rapidly growing gene-testing market. But sustained growth will require hefty capital expenditures. Investors, take note.   |
The Motley Fool
February 4, 2011
Brian Orelli |
Glaxo Sold Quest Shares. Should You? Glaxo has somewhere else to spend the capital. Do you? |
The Motley Fool
July 24, 2006
Ryan Fuhrmann |
The Quest for Market Share Quest Diagnostics' second-quarter earnings mostly meet expectations. What might the future hold for investors? |
The Motley Fool
October 5, 2006
Rich Smith |
Great Chemistry at Lab Corp UnitedHealth Group has canceled its lab-testing contract with Quest and named Lab Corp. as its new service provider. This is an interesting situation for investors. |
The Motley Fool
July 25, 2007
Ryan Fuhrmann |
The Latest Procedure From Quest Diagnostics Quest Diagnostics took a hit earlier this year from the loss of a major contract, but the lab testing firm isn't down for the count. |
The Motley Fool
April 20, 2007
Ryan Fuhrmann |
Diagnosing Quest Diagnostics Quest should recover from a recent, painful contract loss. Shares trade for a reasonable 17.5 times earnings, and even lower multiple of free cash flow. |
The Motley Fool
July 26, 2007
Ryan Fuhrmann |
LabCorp Leaps Forward LabCorp continues to fire on all cylinders. Investors, take note. |
The Motley Fool
January 27, 2009
Brian Orelli |
Testing a Recession-Resistant Hypothesis Quest Diagnostic looks poised for growth even in bad times. |
The Motley Fool
March 31, 2011
David Williamson |
Embarking on a Profitable Quest Quest Diagnostics has been busy, snapping up a pair of smaller players and seeing its share price recover to near 52-week highs. Let's take a look at what these acquisitions mean going forward. |
The Motley Fool
April 19, 2007
Ryan Fuhrmann |
Quest Diagnostics Becomes Un-United: Fool by Numbers The lab-testing firm released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
June 11, 2007
Billy Fisher |
Big Dollars in Diagnostic Deals CIGNA extends multi-year deals to a pair of powerhouses. The Quest agreement is a comfort to investors, who now know that Quest will continue to be a contracted provider for one of the nation's largest health insurers. |
The Motley Fool
October 24, 2006
Ryan Fuhrmann |
LabCorp's Positive Results The good times continue. After taking a major client from Quest Diagnostics, the company reports strong third-quarter earnings. |
The Motley Fool
May 8, 2006
Tom Taulli |
Quest Software: Hugging Microsoft By expanding its products to the Microsoft line, the software company should see more growth. Investors, take note. |
The Motley Fool
February 15, 2007
Ryan Fuhrmann |
LabCorp Takes Names Things are going well at LabCorp, but not so well at Quest Diagnostics. Still, the long-term attractiveness of the lab testing industry is favorable as the industry consolidates and demographics support increasing healthcare services. |
The Motley Fool
February 17, 2005
Rich Smith |
LabCorp Tests Positive The results show strong bottom-line growth for the health-care test provider. Compared to the pricier Quest, it's at least a relative bargain price at which investors can own an interest in this essential piece of the health-care market. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
The Motley Fool
February 13, 2009
Brian Orelli |
Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered. |
InternetNews
January 29, 2004
Clint Boulton |
Active Directory Player To Join Quest Quest Software moves in on smaller rival Aelita in an attempt to shore up its Microsoft infrastructure management provisions. |
The Motley Fool
February 8, 2007
Rich Duprey |
Foolish Forecast: LabCorp Tests Positive The clinical lab-testing outfit is set to report its fourth-quarter 2006 earnings. Investors, here is what you can expect to see. |
Fast Company
November 2009
Stephanie Schomer |
Lost Dollars in Gene Research Billions of R&D dollars flowed to companies promising to cure our ills. Most of those companies are now dead or forgotten. |
The Motley Fool
August 11, 2009 |
3 Stocks Hitting High Notes Tellabs... Human Genome Sciences... priceline.com... etc. |
The Motley Fool
June 2, 2005
Tom Taulli |
Quest Fixes Broken Windows The software company's latest acquisition will help it focus on Microsoft product integration. While a tech acquisition typically rattles investors, it didn't happen with the Vintela acquisition. |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
The Motley Fool
July 22, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Baird turns bullish on Human Genome Sciences. |
The Motley Fool
July 20, 2009 |
3 Stocks Hitting High Notes Oshkosh, Human Genome Sciences, and F5 Networks are among those reaching for the stars. |
The Motley Fool
September 28, 2006
Jack Uldrich |
Is CuraGen Hiding a Genomic Gem? A majority ownership stake in 454 Life Sciences could pay hefty dividends. |
BusinessWeek
August 26, 2010 |
Pockets of Profit in Health-Care Stocks Kris Jenner of the T. Rowe Price Health Sciences Fund on where to find lucrative product pipelines |
The Motley Fool
July 21, 2005
W.D. Crotty |
The Lab Is Fab Laboratory Corporation of America produces more healthy results. Quest is a better value today based on earnings growth, but both companies are an excellent bet. |
The Motley Fool
January 13, 2006
Tim Beyers |
Baby Breaker Birth Announcements We track the week in private equity in search of investments of the future: GeneOhm Sciences.... GeneOhm... etc. |
The Motley Fool
October 25, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Standpoint Capital believes that ExxonMobil, Quest Diagnostics, and Lockheed Martin have nowhere to go but up. |
BusinessWeek
May 10, 2004 |
"You Just Build Up Your Confidence" Quest Diagnostics CEO-in-waiting Surya Mohapatra discusses how the five-year grooming process has helped him enter the big leagues |
The Motley Fool
November 8, 2007
Brian Orelli |
The 2 Sides of Bio-Rad Results for the third quarter reflect stellar clinical sales combined with mediocre laboratory sales. |
The Motley Fool
December 9, 2008
Brian Orelli |
Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences. |
InternetNews
June 1, 2005
Clint Boulton |
Quest Makes ID Management Move Quest Software became the latest management software vendor to bid for products that dole out identity policies, with its push to buy Vintela for $56.5 million in cash. |
The Motley Fool
July 22, 2011
Brian Orelli |
It's How You Finish That Matters Human Genome Sciences gained approval of the first drug developed for lupus in half a century, but in its first full quarter on the market Benlysta was uninspiring. |
The Motley Fool
June 12, 2009
Brian Orelli |
Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side. |
BusinessWeek
May 10, 2004 |
Being a CEO Is Not a Birthright Quest Diagnostics CEO Kenneth Freeman says part of a chief's job is succession planning and discusses his own handover preparations. |
